Cover Image
市場調查報告書

EpiCast Report:氣喘的免疫學預測

EpiCast Report: Asthma - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 273185
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:氣喘的免疫學預測 EpiCast Report: Asthma - Epidemiology Forecast to 2023
出版日期: 2014年09月10日 內容資訊: 英文 87 Pages
簡介

氣喘是全球最常見的慢性病之一,全球有3億人罹患此病。氣喘的患病情形根據國家有所不同,人口比從1%(阿爾巴尼亞)到11%(威爾斯)有很大變化。每年有25萬人因氣喘死亡,如果進行適當的治療,將可以更容易預防。

本報告提供全球主要國家的氣喘的發病情形與今後預測相關分析,疾病的特徵,及目前患者的發病情形,今後10年的患者數量的預測值等等的調查評估,並將其結果依為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 相關調查

第3章 免疫學

  • 疾病的背景情況
  • 風險要素和併發症
    • 家族病史:幼兒期·成人期的氣喘大徵兆
    • 青春期:男生·女生的氣喘風險的變動期
    • 孕婦抽煙:新生兒的氣喘風險增加70%
    • 職場的感染:佔據成人氣喘感染原因的11%
    • 不僅是人種,都市區的生活條件,提高氣喘風險50%
    • 肥胖:氣喘發病風險增加3倍
    • 氣喘患者的90%併發胃食道逆流症(GERD)
    • 氣喘患者的85%併發過敏性鼻炎
    • 恐慌症:氣喘患者共同點,對氣喘管理帶來很大的負面影響
    • 憂鬱症:氣喘患者的39%可能併發
  • 全球各國趨勢
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 澳洲
    • 中國
    • 印度
  • 預測手法
    • 利用的資訊來源
    • 預測的假設·手法
    • 沒利用的資訊來源
  • 氣喘的免疫學的預測(今後11年)
    • 氣喘的終生患病數
    • 終生患者數(各年齡)
    • 終生患者數(男女)
    • 年齡已調整的終生患者數
    • 終生患者數的詳細內容(重症度別)
  • 議論
    • 免疫學的趨勢相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term condition characterized by narrowing of the airways, leading to airflow limitation and airway hyper-responsiveness whenever the lungs come into contact with endogenous and exogenous irritants. Exposure to irritants instigates a series of events, such as swelling of the airways, tightening of the respiratory muscles, and increased mucus production, leading to reduced airflow into the lungs.

In 2013, there were 137.66 million lifetime prevalent cases of asthma in the 10MM, with 82.71 million cases in the US (43.16 million cases) and India (39.55 million cases) combined. GlobalData epidemiologists forecast that there will be approximately 161.02 million lifetime prevalent cases of asthma in the 10MM by 2023, with an overall growth of 17.0% over the next decade.

GlobalData epidemiologists forecast the prevalent cases of asthma in the 10MM from 2013-2023 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of asthma in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the lifetime asthma prevalence using the same study definition, thereby ensuring that the results forecast for each country are comparable. In addition, the lifetime prevalent cases of asthma in each country were further segmented by asthma severity based on the Global Initiative for Asthma guidelines. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

  • The Asthma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for asthma in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It includes a 10-year epidemiological forecast of the lifetime prevalent cases of asthma segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and asthma severity in these markets.
  • The Asthma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global Asthma market.
  • Quantify patient populations in the global Asthma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Asthma therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Family history of asthma is a strong predictor for asthma in children and adults
    • 3.2.2. Puberty alters the risk for asthma in boys and girls
    • 3.2.3. Maternal smoking during pregnancy greatly increases the risk of childhood asthma
    • 3.2.4. Allergens are well-known asthma triggers
    • 3.2.5. Common workplace exposures account for up to 11% of asthma cases in adults
    • 3.2.6. Urban living conditions, not race, increase the risk of asthma by almost 50%
    • 3.2.7. Obesity almost triples the risk of developing asthma
    • 3.2.8. Asthmatics are 90% more likely to develop GERD
    • 3.2.9. 85% of asthmatics have allergic rhinitis
    • 3.2.10. Panic disorders are common in asthmatics and severely impact disease control
    • 3.2.11. 39% of asthmatics are likely to develop depression
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. France
    • 3.3.3. Germany
    • 3.3.4. Italy
    • 3.3.5. Spain
    • 3.3.6. UK
    • 3.3.7. Japan
    • 3.3.8. Australia
    • 3.3.9. China
    • 3.3.10. India
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiology Forecast for Asthma (2013-2023)
    • 3.5.1. Lifetime Prevalent Cases of Asthma
    • 3.5.2. Age-Specific Lifetime Prevalent Cases of Asthma
    • 3.5.3. Sex-Specific Lifetime Prevalent Cases of Asthma
    • 3.5.4. Age-Standardized Lifetime Prevalence of Asthma
    • 3.5.5. Distribution of Lifetime Prevalent Cases of Asthma by Severity
  • 3.6. Discussion
    • 3.6.1. Conclusions on Epidemiology Trends
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: GINA Guidelines for Classification of Asthma by Severity
  • Table 2: Risk Factors and Comorbidities of Asthma
  • Table 3: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011
  • Table 4: Trends in the Prevalence (%) of Self-Reported Asthma in Children in Spain
  • Table 5: Trends in the Lifetime Prevalence (%) of Asthma in the UK
  • Table 6: Lifetime Prevalence (%) of Asthma in Children in China
  • Table 7: Prevalence (%) of Asthma in Children and Adults in India
  • Table 8: Questions Asked to Assess Lifetime Asthma Prevalence
  • Table 9: 10MM, Epidemiological Sources of Lifetime Asthma Prevalence Data
  • Table 10: 10MM, Epidemiological Sources of Asthma Severity Data
  • Table 11: Overview of the Ellis Criteria for Childhood Asthma Severity Classification
  • Table 12: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023
  • Table 13: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), (Row %), 2013
  • Table 14: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, All Ages, N (Row %), 2013
  • Table 15: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Row %), 2013

List of Figures

  • Figure 1: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011
  • Figure 2: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023
  • Figure 3: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), 2013
  • Figure 4: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, N (Millions), 2013
  • Figure 5: 10MM, Age-Standardized Lifetime Prevalence of Asthma, All Ages, Men and Women, %, 2013
  • Figure 6: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Millions), 2013
Back to Top